← British American Tobacco overview

British American Tobacco vs Altria: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

British American Tobacco PLC (BATS.LSE)

Q3 2026
▲2▼1

BAT's smoke-free push gets regulatory tailwind but revenue growth stays soft

  • US opens fast lane for vapes and pouches The Trump administration plans to speed up FDA approval of flavored vapes and nicotine pouches, cutting years of backlog. For BAT, faster clearances mean its Vuse and Velo products can reach US shelves sooner, lifting future sales and profit. Public health and youth-vaping objections could still slow or water down the rules.

    This is the biggest new regulatory force that can lift BAT's smoke-free sales in its largest market.

  • Modern Oral sales surge, buyback and higher EPS guidance BAT raised its full-year earnings guidance and announced a £1.3 billion share buyback after new-category revenue jumped 18%, led by a 66% rise in Modern Oral. Buybacks shrink the number of shares, which lifts earnings per share. Heated tobacco revenue fell nearly 12%, a weak spot.

    It shows the core profit engine and cash returns that directly support the share price.

  • Full-year revenue growth guided to low end BAT reaffirmed 2026 revenue growth at the low end of its 3% to 5% range, signalling softer top-line momentum. The stock is down 13.78% over 90 days. Long-term returns remain strong, and the shares trade below the company's estimated fair value, so the setback is about pace, not survival.

    It is the main new negative that explains why the shares have been weak despite good profit news.

  • Rival ZYN gets first-mover US advantage Philip Morris won the first FDA modified-risk status for a nicotine pouch and is doubling ZYN investment with a $1.2 billion Colorado plant. That gives a rival a head start in the fast-growing US pouch market. BAT's own Modern Oral revenue still rose 65.9%, and it plans a national Velo Max rollout, so it is not standing still.

    It is the key competitive counterweight to BAT's otherwise strong smoke-free growth story.

August 2026
▲2▼1

BAT's smoke-free push gets regulatory tailwind but revenue growth stays soft

  • US opens fast lane for vapes and pouches The Trump administration plans to speed up FDA approval of flavored vapes and nicotine pouches, cutting years of backlog. For BAT, faster clearances mean its Vuse and Velo products can reach US shelves sooner, lifting future sales and profit. Public health and youth-vaping objections could still slow or water down the rules.

    This is the biggest new regulatory force that can lift BAT's smoke-free sales in its largest market.

  • Modern Oral sales surge, buyback and higher EPS guidance BAT raised its full-year earnings guidance and announced a £1.3 billion share buyback after new-category revenue jumped 18%, led by a 66% rise in Modern Oral. Buybacks shrink the number of shares, which lifts earnings per share. Heated tobacco revenue fell nearly 12%, a weak spot.

    It shows the core profit engine and cash returns that directly support the share price.

  • Full-year revenue growth guided to low end BAT reaffirmed 2026 revenue growth at the low end of its 3% to 5% range, signalling softer top-line momentum. The stock is down 13.78% over 90 days. Long-term returns remain strong, and the shares trade below the company's estimated fair value, so the setback is about pace, not survival.

    It is the main new negative that explains why the shares have been weak despite good profit news.

  • Rival ZYN gets first-mover US advantage Philip Morris won the first FDA modified-risk status for a nicotine pouch and is doubling ZYN investment with a $1.2 billion Colorado plant. That gives a rival a head start in the fast-growing US pouch market. BAT's own Modern Oral revenue still rose 65.9%, and it plans a national Velo Max rollout, so it is not standing still.

    It is the key competitive counterweight to BAT's otherwise strong smoke-free growth story.

Latest
▲2▼1

BAT's smoke-free push gets regulatory tailwind but revenue growth stays soft

  • US opens fast lane for vapes and pouches The Trump administration plans to speed up FDA approval of flavored vapes and nicotine pouches, cutting years of backlog. For BAT, faster clearances mean its Vuse and Velo products can reach US shelves sooner, lifting future sales and profit. Public health and youth-vaping objections could still slow or water down the rules.

    This is the biggest new regulatory force that can lift BAT's smoke-free sales in its largest market.

  • Modern Oral sales surge, buyback and higher EPS guidance BAT raised its full-year earnings guidance and announced a £1.3 billion share buyback after new-category revenue jumped 18%, led by a 66% rise in Modern Oral. Buybacks shrink the number of shares, which lifts earnings per share. Heated tobacco revenue fell nearly 12%, a weak spot.

    It shows the core profit engine and cash returns that directly support the share price.

  • Full-year revenue growth guided to low end BAT reaffirmed 2026 revenue growth at the low end of its 3% to 5% range, signalling softer top-line momentum. The stock is down 13.78% over 90 days. Long-term returns remain strong, and the shares trade below the company's estimated fair value, so the setback is about pace, not survival.

    It is the main new negative that explains why the shares have been weak despite good profit news.

  • Rival ZYN gets first-mover US advantage Philip Morris won the first FDA modified-risk status for a nicotine pouch and is doubling ZYN investment with a $1.2 billion Colorado plant. That gives a rival a head start in the fast-growing US pouch market. BAT's own Modern Oral revenue still rose 65.9%, and it plans a national Velo Max rollout, so it is not standing still.

    It is the key competitive counterweight to BAT's otherwise strong smoke-free growth story.

Q2 2026
▲1▼1

BAT cuts 9,000 jobs to save £600m, launches buyback

  • New share buyback announced BAT said it will launch another share buyback during its closed period before July 30 half-year results. Buybacks reduce the number of shares, which can lift the value of those remaining. The stock rose 2% on the news.

    Directly explains a positive price move and shows management's confidence.

  • 9,000 job cuts under Fit2Win BAT is cutting 9,000 jobs (5,500 directly, 3,500 outsourced) to save £600m a year by 2028. Cost savings can boost future profits, but the upfront costs and weak cigarette demand weigh on sentiment. The stock fell 2% on the day.

    This is the main new event and explains both the cost-saving upside and the demand-driven downside.

  • Weaker traditional cigarette demand The restructuring is driven by falling demand for traditional cigarettes. BAT is investing more in smoke-free products like Vuse vapes and Velo pouches, aiming for over half of revenue from these alternatives. The shift pressures current sales but is necessary for long-term growth.

    Highlights the underlying demand problem that forces the restructuring and affects future revenue.

June 2026
▲1▼1

BAT cuts 9,000 jobs to save £600m, launches buyback

  • New share buyback announced BAT said it will launch another share buyback during its closed period before July 30 half-year results. Buybacks reduce the number of shares, which can lift the value of those remaining. The stock rose 2% on the news.

    Directly explains a positive price move and shows management's confidence.

  • 9,000 job cuts under Fit2Win BAT is cutting 9,000 jobs (5,500 directly, 3,500 outsourced) to save £600m a year by 2028. Cost savings can boost future profits, but the upfront costs and weak cigarette demand weigh on sentiment. The stock fell 2% on the day.

    This is the main new event and explains both the cost-saving upside and the demand-driven downside.

  • Weaker traditional cigarette demand The restructuring is driven by falling demand for traditional cigarettes. BAT is investing more in smoke-free products like Vuse vapes and Velo pouches, aiming for over half of revenue from these alternatives. The shift pressures current sales but is necessary for long-term growth.

    Highlights the underlying demand problem that forces the restructuring and affects future revenue.

▲1▼1

BAT cuts 9,000 jobs to save £600m, launches buyback

  • New share buyback announced BAT said it will launch another share buyback during its closed period before July 30 half-year results. Buybacks reduce the number of shares, which can lift the value of those remaining. The stock rose 2% on the news.

    Directly explains a positive price move and shows management's confidence.

  • 9,000 job cuts under Fit2Win BAT is cutting 9,000 jobs (5,500 directly, 3,500 outsourced) to save £600m a year by 2028. Cost savings can boost future profits, but the upfront costs and weak cigarette demand weigh on sentiment. The stock fell 2% on the day.

    This is the main new event and explains both the cost-saving upside and the demand-driven downside.

  • Weaker traditional cigarette demand The restructuring is driven by falling demand for traditional cigarettes. BAT is investing more in smoke-free products like Vuse vapes and Velo pouches, aiming for over half of revenue from these alternatives. The shift pressures current sales but is necessary for long-term growth.

    Highlights the underlying demand problem that forces the restructuring and affects future revenue.

Altria Group (MO)

Q3 2026
▲2▼2

Altria's mixed quarter: dividend and buybacks up, but vape setbacks and volume declines weigh

  • Dividend increase and doubled buybacks Altria raised its dividend 4.7% to $1.11 per share and doubled its stock buyback program to $2 billion, supporting a yield above 6% and returning more cash to shareholders.

    This is a new positive event that directly supports the stock price by increasing shareholder returns.

  • Defensive rotation and potential FDA rule on illicit tobacco Investors rotated into defensive stocks, and a proposed FDA rule requiring foreign tobacco importers to register could reduce illegal competition, helping Altria's pricing power and market position.

    This new development could improve Altria's competitive landscape and pricing ability.

  • Earnings miss, weak guidance, and cigarette volume declines Altria's Q2 earnings missed by $0.02, guidance disappointed, and cigarette volumes fell 4.5% then 10%, with Marlboro's market share slipping to 39.7%, reflecting ongoing demand weakness.

    These new negative results directly hurt investor sentiment and the stock price.

  • Vape setbacks: ZYN authorization, on! share loss, NJOY write-down Philip Morris's ZYN won the first FDA modified-risk authorization, pressuring Altria's on! whose share fell to 13.4%; NJOY ACE's import ban triggered a $1.30 billion write-down, hurting Altria's smoke-free ambitions.

    These new competitive and regulatory setbacks directly threaten Altria's reduced-risk product growth.

August 2026
▲2▼1

Altria's dividend rises even as cigarette volumes fall and smoke-free pivot stumbles

  • Dividend raised again, buyback doubled Altria lifted its quarterly dividend 4.7% to $1.11 per share, its 61st increase in 57 years, and doubled its buyback authorization to $2 billion. Returning $8 billion a year supports the stock by making the 6%-plus yield a reliable income stream.

    The dividend increase and bigger buyback are the period's clearest new positive for the share price.

  • Cigarette volumes fall 10%, Marlboro share slips Full-year domestic cigarette shipment volumes dropped 10.0% and Marlboro's retail share slipped to 39.7%, with discount brands now a third of the market. Falling volumes and shoppers trading down pressure revenue and profits, even though higher prices partly cushion the blow.

    This is the core new negative force: the shrinking cigarette business that funds everything else.

  • Smoke-free pivot stumbles: on! share falls, NJOY hit on! pouch shipments rose 17.6% but its category share fell 4.2 points to 13.4%, and NJOY ACE won't return due to an import ban, triggering a $1.30 billion write-down. The next-generation products meant to replace cigarettes are losing ground to rivals like ZYN.

    The smoke-free stumble is a real counterweight to the dividend story and a new negative for future growth.

  • FDA overhaul could speed vape and pouch approvals The Trump administration plans to streamline FDA review of flavored vapes and nicotine pouches, shortening years-long backlogs. Faster approvals would help Altria's NJOY and on! products reach shelves sooner, though public-health pushback could slow or block the change.

    A potential regulatory tailwind that directly addresses Altria's biggest growth obstacle.

Latest
▲2▼1

Altria's dividend rises even as cigarette volumes fall and smoke-free pivot stumbles

  • Dividend raised again, buyback doubled Altria lifted its quarterly dividend 4.7% to $1.11 per share, its 61st increase in 57 years, and doubled its buyback authorization to $2 billion. Returning $8 billion a year supports the stock by making the 6%-plus yield a reliable income stream.

    The dividend increase and bigger buyback are the period's clearest new positive for the share price.

  • Cigarette volumes fall 10%, Marlboro share slips Full-year domestic cigarette shipment volumes dropped 10.0% and Marlboro's retail share slipped to 39.7%, with discount brands now a third of the market. Falling volumes and shoppers trading down pressure revenue and profits, even though higher prices partly cushion the blow.

    This is the core new negative force: the shrinking cigarette business that funds everything else.

  • Smoke-free pivot stumbles: on! share falls, NJOY hit on! pouch shipments rose 17.6% but its category share fell 4.2 points to 13.4%, and NJOY ACE won't return due to an import ban, triggering a $1.30 billion write-down. The next-generation products meant to replace cigarettes are losing ground to rivals like ZYN.

    The smoke-free stumble is a real counterweight to the dividend story and a new negative for future growth.

  • FDA overhaul could speed vape and pouch approvals The Trump administration plans to streamline FDA review of flavored vapes and nicotine pouches, shortening years-long backlogs. Faster approvals would help Altria's NJOY and on! products reach shelves sooner, though public-health pushback could slow or block the change.

    A potential regulatory tailwind that directly addresses Altria's biggest growth obstacle.

July 2026
▲2▼2

Altria's Smoke-Free Hopes Hit by Q2 Miss and ZYN Rival Edge

  • Q2 earnings miss and soft guidance Altria's Q2 adjusted EPS of $1.48 missed estimates by 2 cents, and full-year guidance midpoint of $5.665 is below the $5.69 consensus. Cigarette shipment volume fell 4.5%, fueling worries about the core business. The stock dropped 9.3% on the news.

    This is the most recent and direct negative driver of MO's price, explaining the sharp sell-off.

  • ZYN gets first FDA modified-risk status for pouches The FDA authorized Philip Morris's ZYN as a modified-risk nicotine pouch, the first in the US. This gives PMI a regulatory edge over Altria's on! pouch, potentially slowing Altria's smoke-free growth and hurting its competitive position.

    This is a new competitive and regulatory setback that directly challenges Altria's smoke-free pivot.

  • FDA proposes foreign tobacco registration rule The FDA proposed requiring foreign tobacco manufacturers to register and list products, closing a loophole that let illegal foreign products flood the US. This would reduce competition for Altria, especially from illicit e-vapor, supporting its pricing power and market share.

    This is a new regulatory tailwind that could benefit Altria by curbing illegal competition.

  • Defensive rotation and dividend appeal With the Fed turning hawkish under new Chair Warsh, investors are rotating into defensive staples. Altria's ~6% dividend yield and 57-year streak of increases make it a top pick, as highlighted by Bank of America and Zacks. This supports demand for the stock.

    This is a new monetary and capital flow driver that boosts MO's attractiveness to income investors.

▲2▼2

Altria's Smoke-Free Hopes Hit by Q2 Miss and ZYN Rival Edge

  • Q2 earnings miss and soft guidance Altria's Q2 adjusted EPS of $1.48 missed estimates by 2 cents, and full-year guidance midpoint of $5.665 is below the $5.69 consensus. Cigarette shipment volume fell 4.5%, fueling worries about the core business. The stock dropped 9.3% on the news.

    This is the most recent and direct negative driver of MO's price, explaining the sharp sell-off.

  • ZYN gets first FDA modified-risk status for pouches The FDA authorized Philip Morris's ZYN as a modified-risk nicotine pouch, the first in the US. This gives PMI a regulatory edge over Altria's on! pouch, potentially slowing Altria's smoke-free growth and hurting its competitive position.

    This is a new competitive and regulatory setback that directly challenges Altria's smoke-free pivot.

  • FDA proposes foreign tobacco registration rule The FDA proposed requiring foreign tobacco manufacturers to register and list products, closing a loophole that let illegal foreign products flood the US. This would reduce competition for Altria, especially from illicit e-vapor, supporting its pricing power and market share.

    This is a new regulatory tailwind that could benefit Altria by curbing illegal competition.

  • Defensive rotation and dividend appeal With the Fed turning hawkish under new Chair Warsh, investors are rotating into defensive staples. Altria's ~6% dividend yield and 57-year streak of increases make it a top pick, as highlighted by Bank of America and Zacks. This supports demand for the stock.

    This is a new monetary and capital flow driver that boosts MO's attractiveness to income investors.